Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova et al. · The Lancet · 2010 · 7.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

<i>HER2</i> Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial

Edith A. Perez, Vera J. Suman, Nancy E. Davidson et al. · Journal of Clinical Oncology · 2006 · 443 citations · Full text

Medicine, Oncology, Pathology +17

RETRACTED: Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling

Qing‐Bai She, Sarat Chandarlapaty, Qing Ye et al. · PLoS ONE · 2008 · 317 citations · Full text

Medicine, Cancer Biology, Cell Biology +17

Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion.

Daniel K. Podolsky, K. Lynch-Devaney, J.L. Stow et al. · Journal of Biological Chemistry · 1993 · 267 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

Alberto Gallardo, Enrique Lerma, Daniel Escuín et al. · British Journal of Cancer · 2012 · 231 citations · Full text

Medicine, Molecular Medicine, Oncology +17